Article Text

other Versions

PDF
Letter
Baclofen in community paediatric management of hypertonia
  1. Ram Kumar1,
  2. Binu George2
  1. 1Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
  2. 2Department of Paediatric Neurodisability, Great North Children's Hospital, Newcastle upon Tyne, UK
  1. Correspondence to Dr Ram Kumar, Department of Neurology, Alder Hey Children's NHS Foundation Trust, Eaton Road, West Derby, Liverpool L12 2AP, UK; ram.kumar{at}alderhey.nhs.uk

Statistics from Altmetric.com

We wish to draw attention to the NICE guidelines for spasticity management in children, in particular, recommendations on oral baclofen prescribing.1 Despite its reported efficacy in reducing spastic tone in controlled studies, there is little information on the effectiveness, safety and quality of prescribing of baclofen in real-life practice.2 We noted that non-specialist (paediatric neurology, neurodisability) paediatricians express a lack of experience and knowledge in managing hypertonia with baclofen. The community paediatric setting is where children with hypertonia due to cerebral palsy, the predominant underlying condition, are routinely managed, as opposed to specialist tone management clinics, where controlled studies are typically performed. We conducted a baseline audit …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.